GRI Bio, Inc. (GRI) Key Metrics
GRI valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $3.0M
- Enterprise value
- −$6.3M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.61
GRI key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsGRI returns How much profit the business earns on the capital it uses.
GRI financial health Debt, liquidity and how easily interest is covered.
GRI efficiency & capital use Working capital cycle and where the cash goes.
GRI valuation history
GRI returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GRI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GRI cash returned to shareholders
GRI price vs earnings per share
GRI key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | — | $1.94B | — | — | — | — | — | — |
| Enterprise value | — | $1.93B | — | — | — | — | — | — |
| Price / sales | — | 86.0 | — | — | — | — | — | — |
| Price / book | — | 480.5 | — | — | — | — | — | — |
| EV / sales | — | 85.7 | — | — | — | — | — | — |
| Earnings yield | — | −0.4% | — | — | — | — | — | — |
| Free cash flow yield | — | −0.4% | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | 0.0% | — | — | — | — | — | — |
| Share price at fiscal year-end | $6.92 | $394.13 | $16,676.66 | $376,849.20 | $999,949.86 | — | — | — |
| Per share | ||||||||
| Revenue per share | — | $4.58 | — | — | — | — | — | — |
| Earnings per share | — | −$1.67 | — | — | — | — | — | — |
| Operating cash flow per share | — | −$1.75 | — | — | — | — | — | — |
| Free cash flow per share | — | −$1.75 | — | — | — | — | — | — |
| Cash per share | — | $1.02 | — | — | — | — | — | — |
| Book value per share | — | $0.82 | — | — | — | — | — | — |
| Tangible book value per share | — | $0.82 | — | — | — | — | — | — |
| Capex per share | — | $0.00 | — | — | — | — | — | — |
| Debt per share | — | $0.02 | — | — | — | — | — | — |
| Shares outstanding | — | 4.9M | — | — | — | — | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −238.2% | −382.5% | — | — | — | — | −205.8% | — |
| Return on assets (ROA) | −166.0% | −188.8% | −780.9% | — | −265.8% | −96.8% | −141.0% | −674.7% |
| Return on tangible assets | −138.0% | −143.0% | −441.0% | −839.9% | −715.1% | −265.0% | −81.0% | −674.7% |
| Free cash flow margin | — | −38.2% | −41.3% | — | — | — | — | — |
| Financial health | ||||||||
| Total debt | $71,000 | $119,000 | $14,000 | $673,000 | $3.6M | $336,000 | $340,021 | — |
| Cash & short-term investments | $8.2M | $5.0M | $1.8M | $9,000 | $90,000 | $109,000 | $3.8M | $612,652 |
| Net debt | −$8.2M | −$4.9M | −$1.8M | $664,000 | $3.5M | $227,000 | −$3.5M | −$612,652 |
| Debt / equity | 0.01 | 0.03 | 0.05 | — | — | — | 0.11 | — |
| Debt / assets | 0.01 | 0.02 | 0.00 | 1.76 | 16.58 | 0.35 | 0.08 | — |
| Current ratio | 3.25 | 3.43 | 1.09 | 0.16 | 0.02 | 0.30 | 4.86 | 1.31 |
| Quick ratio | 3.25 | 3.43 | 1.09 | 0.16 | 0.02 | 0.30 | 4.86 | 1.31 |
| Interest coverage | — | — | -5.5 | -3.4 | -1.9 | -42.9 | -16.0 | — |
| Working capital | $5.9M | $4.0M | $237,000 | −$1.7M | −$4.8M | −$1.6M | $3.1M | $151,347 |
| Invested capital | −$2.1M | −$877,000 | −$1.5M | −$961,000 | −$1.2M | −$1.2M | −$267,071 | −$459,713 |
| Tangible asset value | $6.0M | $4.0M | $259,000 | −$1.6M | −$4.7M | −$1.5M | $3.2M | $152,939 |
| Net current asset value | $5.9M | $3.9M | $237,000 | −$1.7M | −$4.8M | −$1.7M | $2.9M | $151,347 |
| Graham net-net per share | — | $0.68 | — | — | — | — | — | — |
| Capital allocation | ||||||||
| Dividends paid | — | — | $2.9M | $3.4M | — | — | — | — |
| Share buybacks (net) | $1,000 | $1,000 | $0 | $124,000 | $0 | — | — | — |
| Capex / revenue | — | 0.0% | 0.0% | — | — | 2.0% | — | — |
| Capex / depreciation | 0.75 | 0.00 | 2.00 | 1.00 | 0.00 | 0.03 | 0.01 | 3.60 |
| Stock-based compensation / revenue | — | 0.7% | 1.8% | — | — | — | — | — |
| R&D / revenue | — | 16.7% | 14.8% | — | — | 264.0% | — | — |
| SG&A / revenue | — | 20.1% | 37.5% | — | — | 1,195.0% | — | — |
| Efficiency | ||||||||
| Days payables outstanding | 124,738.8 | 105,256.9 | 8,657.5 | 4,931.1 | 3,207.5 | 2,687.0 | 132,329.1 | 170,937.5 |
| Payables turnover | 0.00 | 0.00 | 0.04 | 0.07 | 0.11 | 0.14 | 0.00 | 0.00 |
| Asset turnover | 0.00 | 5.18 | 13.04 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 |
| Average payables | $1.4M | $1.2M | $1.4M | $675,500 | $641,500 | $736,164 | $266,471 | $286,613 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from GRI's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GRI valuation and financial ratios
GRI Bio earned a return on equity of −238.2% in fiscal 2025. It ended the year with $0.1 million of debt and $8.2 million in cash and short-term investments, a net cash position of $8.2 million. It returned $0.0 million to shareholders: $0 in dividends and $0.0 million in share buybacks.
See the GRI income statement, the GRI chart for price history, or the GRI stock overview for the latest quote and news.
GRI key metrics FAQ
What is GRI Bio's return on equity?
GRI Bio's return on equity (ROE) was −238.2% in fiscal 2025: net income of -$12.0 million on average shareholders' equity of $5.0 million.
How much debt does GRI Bio have?
GRI Bio had total debt of $0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
Does GRI Bio buy back its shares?
Yes. GRI Bio spent $0.0 million on net share repurchases in fiscal 2025.
What is GRI Bio's current ratio?
GRI Bio's current ratio was 3.25 at the end of fiscal 2025: current assets were 3.25 times current liabilities.